^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TP53 mutation + MDM2 mutation

    i
    Other names: TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1, MDM2, HDM2, MGC5370, MDM2 proto-oncogene, E3 ubiquitin protein ligase
    Entrez ID:
    7157; 4193
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1year
    Novel Hypomethylating Agent Ntx-301 Exhibits Anti-Leukemia Activity in Venetoclax-Resistant and TP53-Mutant AML (ASH 2023)
    Additionally, NTX-301 treatment increased caspase-8 and cleaved-caspase-8 in AML cells independent of TP53 mutation status, consistence with reports showing caspase-8 hypermethylation in AML and supporting that activation of caspase-8-mediated extrinsic apoptosis as a mechanism of NTX-301 action. In conclusion, our data suggest that NTX-301 has more potent anti-leukemia activities compared to current HMA in clinic and synergizes with venetoclax in venetoclax-resistance and TP53-mutant AML and AML stem/progenitor cells, and warrants clinical evaluation
    IO biomarker
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • MCL1 (Myeloid cell leukemia 1) • MDM2 (E3 ubiquitin protein ligase) • CD38 (CD38 Molecule) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • DNMT1 (DNA methyltransferase 1) • CASP8 (Caspase 8)
    |
    TP53 mutation • TP53 wild-type • MCL1 overexpression • MCL1 expression • MDM2 mutation • TP53 mutation + MDM2 mutation
    |
    Venclexta (venetoclax) • NTX-301